Alpha and Omega Semiconductor Limited (NASDAQ:AOSL) will release its financial results for the fiscal quarter ended September 30, 2010 on Thursday, October 28, 2010, after the market closes.
The press release will be followed by a conference call and live webcast at 2:00 p.m. PT / 5:00 p.m. ET, which will be open to the public.
Alpha and Omega Semiconductor Limited engages in the design, development, and supply of a range of power semiconductors worldwide.
Power3 Medical Products, Inc. (PWRM.OB) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. The tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Power3 Medical Products, Inc. previously has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc., a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy.
PWRM plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
For more information about this company please visit http://www.power3medical.com
Provident Financial Holdings, Inc. (NASDAQ:PROV), the holding company for Provident Savings Bank, F.S.B., reported first quarter earnings for the fiscal year ending June 30, 2011.
For the quarter ended September 30, 2010, PROV reported net income of $4.53 million, or $0.40 per diluted share (on 11.36 million average shares outstanding), compared to a net loss of $(5.02) million, or $(0.82) per diluted share (on 6.11 million average shares outstanding), in the comparable period a year ago.
The first quarter of fiscal 2011 net income was primarily attributable to a substantial decrease in the provision for loan losses and an increase in non-interest income, partly offset by a decrease in net interest income (before provision for loan losses) and an increase in operating expenses as compared to the same period last year.
Provident Financial Holdings, Inc. operates as the holding company for Provident Savings Bank, F.S.B. that provides various financial services to consumers and small to mid-sized businesses in the Inland Empire region of southern California.
Vical Incorporated (NASDAQ:VICL) reported that the company’s Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company’s herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).